OC 21 - Novel hemophilia treatments, pre-clinical

Moderator(s)

• 

  Runhui Wu, PhD, MD

  Professor
  Department of Hematology, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, 100045, China
  Beijing, Beijing, China (People's Republic)
• 

  Saskia Prasca, MEDICAL DOCTOR

  Hematologist and hemophilia specialist
  Medicarte, Antioquia, Colombia

Presentations:

• 14:45 – 15:00 ICT

  Novel FVIIIa-mimetic molecule with the potential to be the first oral treatment for severe hemophilia A
  

  Presenting Author: Jacob Lund, PhD – Novo Nordisk A/S, Måløv, Denmark

  Co-Author: Jais R. Bjelke – Novo Nordisk A/S

  Co-Author: Daniele Granata – Novo Nordisk A/S

  Co-Author: Thomas Egebjerg – Novo Nordisk A/S

  Co-Author: Eva Johansson – Novo Nordisk A/S

  Co-Author: Wang Zhuoran – Novo Nordisk A/S

  Co-Author: Pierre-Louis Bardonnet – Novo Nordisk A/S

  Co-Author: Pingping Chen – Novo Nordisk A/S

  Co-Author: Mads Bjelke – Novo Nordisk A/S

  Co-Author: Andreas Vegge – Novo Nordisk A/S
• 15:00 – 15:15 ICT

  Design of a Superior Factor VIII Mimetic with Membrane Binding Properties and Built-in Reversibility
  

  Presenting Author: Shekhar Kumar, PhD – Research Institute, Children's Hospital of Philadelphia, Philadelphia, PA

  Co-Author: Sriram Krishnaswamy – Research Institute, Children's Hospital of Philadelphia, Philadelphia, PA
• 15:15 – 15:30 ICT

  The in vitro and in vivo hemostatic efficacies of a novel FVIIIa-mimetic bispecific antibody, SS315, for the treatment of Hemophilia A.
  

  Co-Author: Luyan Zhu – Beijing Gensciences Inc., Beijing, China

  Presenting Author: Weichuan Mo, PhD – Beijing Gensciences Inc., Beijing, China

  Co-Author: Yuanwu Liu – Beijing Gensciences Inc., Beijing, China

  Co-Author: Xin Chen – Zhengzhou Gensciences Inc., Zhengzhou, China

  Co-Author: Feng Mao – Beijing Gensciences Inc., Beijing, China

  Co-Author: Chenning Qu – Zhengzhou Gensciences Inc., Zhengzhou, China

  Co-Author: Hongsheng Su – Beijing Gensciences Inc., Beijing, China
• 15:30 – 15:45 ICT

  Genetic Ablation of Anticoagulant Protein S Promotes Joint Health in Hemophilia A
  

  Presenting Author: Raja Prince-Eladnani – Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Switzerland; Department for BioMedical Research, University of Bern, Switzerland

  Co-Author: Sara Calzavarini – Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, CH-3010 Bern, Switzerland. Department for BioMedical Research, University of Bern, Murtenstrasse 40, CH-3010 Bern, Switzerland

  Co-Author: Maria Desiré Reina Caro – Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, CH-3010 Bern, Switzerland. Department for BioMedical Research, University of Bern, Murtenstrasse 40, CH-3010 Bern, Switzerland

  Co-Author: Beat Haenni – Institute of Anatomy, University of Bern, Baltzerstrasse 2, 3012 Bern

  Co-Author: Anne Angelillo-Scherrer, MD – Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, CH-3010 Bern, Switzerland. Department for BioMedical Research, University of Bern, Murtenstrasse 40, CH-3010 Bern, Switzerland
• 15:45 – 16:00 ICT

  An Open-label,Dose-Escalation,Multicenter Phase I Study to Evaluate the Safety,Immunogenicity,and Pharmacokinetics/pharmacodynamics（PK/PD）of Single Dose SS109 in Hemophilia A/B patients with Inhibitor
  

  Presenting Author: Mankai Ju, MD – State Key Laboratory of Experimental Hematology, Tianjin Laboratory of Blood Disease Gene Therapy, CAMS Key Laboratory of Gene Therapy for Blood Diseases, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P.R. China.

  Co-Author: Feng Xue, MD – State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin 300020, China

  Co-Author: Zeping Zhou – The Second Affiliated Hospital of Kunming Medical University

  Co-Author: Zhenyu Li – The Affiliated Hospital of Xuzhou Medical College, Jiangsu, P.R. China

  Co-Author: Hu Zhou, MD – Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital

  Co-Author: Ning Huang – The First Affiliated Hospital of Shandong First Medical University, Shandong, P.R. China

  Co-Author: Wei Zhao – The First Affiliated Hospital of Shandong First Medical University, Shandong, P.R. China

  Co-Author: Changcheng Zheng – The First Affiliated Hospital of University of Science and Technology of China,Anhui, P.R. China

  Co-Author: Aizong Shen – Anhui Provincial Hospital, Anhui, P.R. China

  Co-Author: Chenghao Jin – Jiangxi Provincial People's Hospital, Jiangxi, P.R. China

  Co-Author: Jianfang Chen – The Second Hospital of Shanxi Medical University, Shanxi, P.R. China

  Co-Author: Yanping Song – Xi'an Central Hospital, Shanxi, P.R. China

  Co-Author: Renchi Yang, MD – Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College